Holen Sie sich die Stockscreener-App
23.46
0.09%
0.02
Handel nachbörslich:
23.46
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ASRT?
Forum
Prognose
Aktiensplit
Assertio Holdings Inc Aktie (ASRT) Neueste Nachrichten
Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit - MSN
Assertio Announces Amended And Restated Merger Agreement With Garda Therapeutics >ASRT - Moomoo
Assertio Deadline Alert - TMX Newsfile
$HAREHOLDER ALERT: The M&A Class Action Continues to Investigate the Merger-ASRT, SILA, KW, and UNF - The Malaysian Reserve
ASRT Stock Price, Quote & Chart | ASSERTIO HOLDINGS INC (NASDAQ:ASRT) - ChartMill
Assertio gets sweetened $153M buyout offer from Garda Therapeutics - MSN
Zydus buys Assertio for $166 million to deepen US specialty and oncology presence - MSN
Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc.ASRT - Business Wire
Are SEM, UNF, CNTA, ASRT Obtaining Fair Deals for their Shareholders? - Sahm
Zydus offers $23.50 cash per share to buy Assertio (ASRT) — Board backs deal - Stock Titan
Zydus (NASDAQ: ASRT) offers $23.50 per share in cash tender for Assertio - Stock Titan
Assertio Therapeutics to be acquired by Zydus Worldwide - TipRanks
Assertio Holdings to be acquired by Zydus Worldwide in $23.50 per share cash deal - Investing.com Australia
Assertio Holdings, Inc. Announces Pre-Commencement Issuer Tender Offer and Merger Update – SEC Form 8-K Filing May 18, 2026 - Minichart
Assertio to be acquired in $23.50/share cash tender offer by Zydus - TradingView
Assertio (ASRT) to be acquired for $23.50 per share; tender offer starts May 18, 2026 - Stock Titan
Assertio (ASRT) moves 17.0% higher: Will this strength last? - MSN
Assertio's Acquisition: What's the Deal and Why Now - Kavout
Zydus Expands US Cancer Drug Business with Assertio Acquisition - Chemical Industry Digest
Director of Assertio (NASDAQ: ASRT) makes 13,332-share stock gift - Stock Titan
Assertio Holdings (ASRT) price target decreased by 12.42% to 24.34 - MSN
Zydus-Assertio Deal: US Revenue Might Peak In 2029 But Rolvedon Promises More - Citeline News & Insights
symbol__ Stock Quote Price and Forecast - CNN
Zydus Lifesciences Buys Assertio In US To Strengthen Cancer Treatment Push - Siliconindia
Zydus to Acquire US Oncology Pharma Firm Assertio in USD 166 Million Deal - Medical Dialogues
Zydus (ASRT) proposes $23.50 cash tender offer; Schedule TO forthcoming - Stock Titan
Zydus to acquire Assertio in $166m deal - Yahoo Finance
Zydus Life spurts as board to mull share buyback; arm signs deal to acquire Assertio - Business Standard
Zydus to acquire US firm Assertio for $166.4 million - Ahmedabad Mirror
Buyback and Acquisition Announcement: This pharma company shares BIG update for shareholders - Zee Business
Zydus Lifesciences shares jump 6% on buyback buzz; co announces $166 mn Assertio acquisition - The Economic Times
Zydus Lifesciences acquires Assertio in ₹1,570 crore US expansion push - domain-b.com
Zydus Worldwide DMCC to Acquire Entire Stake in Assertio Holdings for USD 166.4 Million - scanx.trade
Zydus to acquire US-based Assertio for $166.4 million - The Indian Express
Zydus to acquire US-based Assertio for $166.4 M to support oncology therapies - BioSpectrum India
Zydus Lifesciences arm to acquire US oncology firm Assertio - VCCircle
Zydus to buy Assertio for $166.4 million - The Economic Times
Zydus to acquire Assertio in all-cash tender offer - Express Pharma
Zydus Lifesciences to acquire Assertio for USD 166.4 mn - ET BrandEquity
Zydus and Assertio Holdings enter into an agreement for Zydus to acquire Assertio in an all-cash tender offer - IndiaMedToday
Zydus Lifesciences to Acquire Assertio for $166.4 Million - outlookbusiness.com
Zydus buys US specialty drugmaker Assertio in Rs 1,600 crore all-cash deal - TradingView
Zydus Lifesciences arm to acquire U.S. oncology firm Assertio for $166 million - The Hindu
ASRT | Assertio Holdings, Inc. Common FinancialsIncome Statement - Quiver Quantitative
5.02%
5.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):